SK Bioscience Advances Universal Coronavirus Vaccine into Phase 1/2 Trials
Event summary
- SK Bioscience initiated a global Phase 1/2 clinical trial for GBP511, a universal vaccine targeting the Sarbecovirus family, including SARS-CoV-2 and related coronaviruses.
- The trial, conducted in Australia, will enroll 368 adults aged 18 and older, evaluating safety, tolerability, and immunogenicity across low-, medium-, and high-dose cohorts with or without an adjuvant.
- GBP511 leverages SKYCovione's recombinant protein-based platform and nanoparticle technology developed by the Institute for Protein Design at the University of Washington.
- CEPI has designated the SARS-coronavirus family as a 'prototype pathogen' and is supporting the development of broadly protective coronavirus vaccines.
The big picture
SK Bioscience's entry into global Phase 1/2 clinical development for a universal coronavirus vaccine marks a significant step in pandemic preparedness. The initiative aligns with CEPI's emphasis on broadly protective vaccines and addresses the limitations of variant-specific approaches. The global COVID-19 vaccine market is transitioning from short-term demand to sustained growth, with next-generation technologies like universal vaccines expected to drive new market demand.
What we're watching
- Clinical Trial Progress
- The pace at which GBP511 advances through Phase 1/2 trials and demonstrates cross-reactive immune responses across the Sarbecovirus family.
- Market Dynamics
- Whether SK Bioscience can capitalize on the projected growth of the COVID-19 vaccine market, estimated to reach USD 83.4 billion by 2032.
- Regulatory Approval
- The likelihood of regulatory approval for GBP511, given the favorable safety profile and robust immunogenicity demonstrated by SKYCovione.
Related topics